PYY 1875
Alternative Names: NN 9775; NNC 01651875; PYY-1875Latest Information Update: 31 Mar 2023
At a glance
- Originator Novo Nordisk
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
Most Recent Events
- 06 Dec 2022 Novo Nordisk completes a phase II trial in Obesity (Adjunctive treatment) in USA (SC) (NCT04969939)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Obesity(Combination therapy) in USA (SC, Injection)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Obesity(Monotherapy) in USA (SC, Injection)